ITP/TTP and aHUS
Description
Upon viewing this session, you will be able to:
• apply the immature platelet fraction in the work up of thrombocytopenia
• summarize the efficacy of upfront dexamethasone and eltrombopag in ITP
• identify predictors of response to TPO-receptor agonists
• review the evidence supporting fostamatinib and dapsone for refractory ITP
• summarize the efficacy of caplacizumab in TTP
• discuss the use of low dose rituximab in acute TTP
• describe the long-term renal and cardiovascular sequelae of atypical HUS
• apply the immature platelet fraction in the work up of thrombocytopenia
• summarize the efficacy of upfront dexamethasone and eltrombopag in ITP
• identify predictors of response to TPO-receptor agonists
• review the evidence supporting fostamatinib and dapsone for refractory ITP
• summarize the efficacy of caplacizumab in TTP
• discuss the use of low dose rituximab in acute TTP
• describe the long-term renal and cardiovascular sequelae of atypical HUS
Presenters
- Wendy Lim
Pricing
| Member Type | Price |
|---|---|
| List Price | $30.00 |
| Active, International, Emeritus, and Honorary Members | $20.00 |
| Associate, International Associate, Student, and Resident Members | $20.00 |
ASH Meeting on Hematologic Malignancies
Hear the latest developments in clinical care, and get answers to your most challenging patient care questions.
Learn more
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
Copyright © 2021 by American Society of Hematology